Phenylbutazone is a potent anti-inflammatory agent. It was effective in modifying or causing the resolution of superficial thrombophlebitis in the extremities of 132 patients in whom this condition had proven refractory or difficult to manage. The short course of treatment which proved necessary to accomplish this end, makes this drug a practical and relatively safe addition to the management of superficial vein inflammation.
T HE rapid subsidence of the inflammation in superficial veins of the limbs was described recently' in 50 patients treated with phenylbutazone.* This drug was employed because the superficial phlebitis had been refractory to other measures of treatment, or because it was so vexing a complication that the use of any rapid and effective method was felt to be warranted.
Since publishing this earlier report, 82 new patients have been added, making a total of 132 cases in which phenylbutazone was given in treatment. Our further experiences with phenylbutazone in the management of superficial thrombophlebitis are the subject of this study.
METHOD
Patients were selected for one of the above reasons. The accessibility of the inflamed veins made the diagnosis of a phlebitis an accurate one and simplified observing the effects of treatment. Color photographs at various stages in the course of the illness made convincing and permanent records.
The 132 patients were screened from a larger group, whose size was difficult to pinpoint because of the diverse sources from which they were obtained. A reasonable estimation would be that they were derived from 600 to 700 individuals who had presented themselves to their private physician, to the hospital ward or anticoagulants and/or antibiotics. Later on when it became apparent how relatively simple and safe it was to treat this condition in the manner described, more and more patients were treated with phenylbutazone from the start. We employed a dosage recommended for the treatment of rheumatic conditions. Thus, each individual was instructed to take 200 mg. three times a day for three days and then 100 mg. three times a day for four more days or a total dose of 3 Gm. for the week. In order to prevent gastric irritation the medication was taken after meals. Patients were advised to take a proprietary antacid or a glass of milk if sourness or "acid stomach" did occur.
No patient was kept in bed unless the pain was severe enough to incapacitate him or the systemic reaction to the phlebitis made bedrest advisable. As a rule within 24 hours, most patients were able to get up and walk about; all were able to do so by the end of the second day. No attempt was made to limit fluids or salt intake for the sake of the phlebitis alone during the week of treatment although each patient was requested to drink or eat the equivalent of two oranges a day as a source of potassium ion. None of the patients studied had gout or polycythemia vera.
The many possible grave complications reported from use of the drug alerted us for early toxic reactions. The early and marked regression seen 8 to 12 hours after use of phenylbutazone in the human subject corresponds quite closely to the changes seen inl experimentally induced venous thrombosis.9
We have divided the patients studied into five groups in an attempt to indicate the (2) in malignant disease, (3) in thromboangiitis obliterans, (4) following intravenous injection of solutions for therapeutic or diagnostic intent and (5) in clinically normal veins of spontaneous origin as in idiopathic migratory thrombophlebitis.
COMMENT Phlebitis of the superficial veins in the arms and legs is not always a simple and easy condition to treat. On occasion, inflammatory changes may persist despite the usually effective management with bed rest, soaks and anticoagulant drugs. In coexisting conditions, such as pregnancy, congestive heart failure or pre-and postoperative states, one wishes there were some rapid and effective means of coping with this troublesome complication. We believe that phenylbutazone does this. Its use in superficial phlebitis was empiric, based upon its potent anti-inflammatory behavior, which was evident in a variety of disorders. [10] [11] [12] [13] Our previous experience with phenylbutazone in the management of acute superficial thrombophlebitis' is confirmed. The anti-inflammatory and analgesic properties of this drug have a marked influence on the course of this disorder, causing resolution of considerable degree within 24 to 48 hours of its use. This is all the more impressive because the treated patients represented a difficult and refractory group.
The superficial phlebitis was found most frequently in the patient with varicose veins. Of this group, 102 of 104 patients were treated expeditiously and effectively by a single course of treatment lasting one week or less. As the phlebitis is only an incident in the course of this disorder, more specific measures, i.e., saphenous vein ligation and stripping, were recommended after a period of convalescence. instanies, that mo)dification was attempted with pheiyvlbuitazo-)nie. lit each of these three instaitwes of iatrogeitc disease, the troublesome local and systemic maitifestations were dramatically aborted. In the remaining two cases, the superficial phlebitis was the result of intravenous infusions in postoperative cases. Noradrenalin was the offending agent in one, and glucose in saline in the other. The involved veins were rapidly and successfully resolved with the aid of phenylbutazonie.
In the six patients comprising the fifth and last group, i.e., patients with superficial phlebitis in presumably normal veins, some interesting facts caine to light. Three patients had typically recurrentt (migratory) superficial thrombophlebitis without clinical involvement of the peripheral arteries. In one the condition had been present for 13 years, in another for five years and in a third for two years. Each one was completely symptom-free provided a maiiitenance dose of phenylbutazoiie (100 to 200 mg.) daily was taken. The drug has been taken, therefore, for eight months, two years and two and one half years, respectively, and without incident. In connection with this long term use, it was interesting to read of similar freedom from toxicity in the management of arthritics who were maintained on minimal dosage but exposed to prolonged adminiistration of phenylbutazoine.14 Another patient in this group developed a spontaneous phlebitis of one of the antecubital veins while receiving hydrocortonie for rheumatoid polyarthritis.
This and more serious vascular complications are seen not too infrequently in the course of long continued use of the eorticosteroids.it
The phlebitis responded quite promptly to phenylbutazone. The fifth and sixth patients were both women who developed spontaneous phlebitis of the antecubital vein of the homolateral arm following radical mastectomy. In the one instance, the time relationship to the operation was one and one half years, in the other five days. In neither was there clinical evidence of metastatic disease and in both the phlebitis regressed completely with phenylbutazone.
As previously stated, the major premises for limiting this study to patients with superficial phlebitis were for the sake of accuracy in diagnosis and for simplicity and convenience TREATMENT OF THROMBOPHLEBITIS WITH PHENYLBUTAZONE in following the effects of treatment. This choice was fortunate. Had we chosen to study deep vein phlebitis, it is possible that the study might have been prematurely terminated. On the occasions when we used phenylbutazone in the treatment of the deep vein variety, the pain is definitely lessened as are the systemic reactions. However, the most prominent feature of a deep vein thrombosis, the swelling of the limb distal to the obstructed segment, remains unchanged. This is understandable because such swelling represents the engorgement secondary to mechanical plugging in the main channels of venous return rather than the localized inflammatory edema of a superficial phlebitis. We have, therefore, continued to advocate its use in the latter condition rather than in deep vein phlebitis.
SUMMARY AND CONCLUSIONS One hundred and thirty-two patients with superficial thrombophlebitis in the extremities were treated with phenylbutazone (Butazolidin).
Although the causes of the phlebitis were varied, being associated with varicose veins in most cases, but also as part of Buerger's disease, following the intravenous administration of fluids or drugs in others or as complication or manifestation of malignant disease, the response to the drug was a remarkably uniform and rapid regression of the vein inflammation.
Treatment with phenylbutazone (Butazolidin) was limited to one week during which a total of 3.0 to 3.5 Gm. were administered.
With this small and limited dosage, major toxic reactions were not seen. In a few patients, short-lived skin eruptions were seen.
With phenylbutazone (Butazolidin) treatment is simplified in that the patient remains ambulant and local management is eliminated. 
